source
- Poll Shows Readers Most Excited for PersevERA BC Trial Data at ASCO 2026As the 2026 ASCO Annual Meeting draws near, a recent poll asked oncology readers which breast-cancer abstract they are most looking forward to. Respondents could choose among several late-breaking…
- FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancerThe FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…